[go: up one dir, main page]

ATE396186T1 - Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 - Google Patents

Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5

Info

Publication number
ATE396186T1
ATE396186T1 AT02776076T AT02776076T ATE396186T1 AT E396186 T1 ATE396186 T1 AT E396186T1 AT 02776076 T AT02776076 T AT 02776076T AT 02776076 T AT02776076 T AT 02776076T AT E396186 T1 ATE396186 T1 AT E396186T1
Authority
AT
Austria
Prior art keywords
heteroaryl
glutama
metabotropic
modulators
receptor
Prior art date
Application number
AT02776076T
Other languages
English (en)
Inventor
Nicholas Cosford
Jeffrey Roppe
Chixu Chen
Nicholas Smith
Thomas Reger
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE396186T1 publication Critical patent/ATE396186T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
AT02776076T 2001-10-04 2002-10-01 Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 ATE396186T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32713201P 2001-10-04 2001-10-04

Publications (1)

Publication Number Publication Date
ATE396186T1 true ATE396186T1 (de) 2008-06-15

Family

ID=23275282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02776076T ATE396186T1 (de) 2001-10-04 2002-10-01 Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5

Country Status (8)

Country Link
US (1) US7253190B2 (de)
EP (1) EP1434773B1 (de)
JP (1) JP4303109B2 (de)
AT (1) ATE396186T1 (de)
AU (1) AU2002341921B2 (de)
CA (1) CA2462289C (de)
DE (1) DE60226756D1 (de)
WO (1) WO2003029210A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051833A2 (en) * 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
CA2478799C (en) 2002-03-12 2009-12-29 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
AU2003264047B2 (en) 2002-08-08 2008-06-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
NZ537980A (en) 2002-08-23 2007-08-31 Rigel Pharmaceuticals Inc Pyridyl substituted heterocycles useful for treating or preventing HCV infection
DE60306193T2 (de) 2002-11-27 2006-10-12 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield 1,2,3-triazolamid-derivate als cytokininhibitoren
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004089303A2 (en) * 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2004087653A2 (en) * 2003-04-03 2004-10-14 Merck & Co., Inc. 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7531529B2 (en) * 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
CA2537141A1 (en) * 2003-09-02 2005-03-10 Merck And Co., Inc. Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
RU2006118021A (ru) * 2003-12-19 2007-12-10 АстраЗнека АБ (SE) Замещенные пиридин-2-ил-тетразолы (варианты), фармацевтическая композиция, лекарственное средство, способ лечения расстройств с их использованием, способ ингибирования активации метаботропных глютаматных рецепторов -5 и способ получения пиридилпроизводных
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CN1933838A (zh) * 2004-02-12 2007-03-21 默克公司 作为代谢型谷氨酸受体-5调节剂的联吡啶酰胺
AU2005214380A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
JP2007523181A (ja) * 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
US20070197549A1 (en) * 2004-02-18 2007-08-23 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
KR20070027503A (ko) * 2004-02-18 2007-03-09 아스트라제네카 아베 트리아졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (en) * 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20090137637A1 (en) * 2004-12-08 2009-05-28 Pfizer Inc. Tetrazolyl-Methylene Amino Acid Derivatives
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
HUP0500921A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Tetrazole derivatives, process for their preparation and their use
US7951824B2 (en) * 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
HUE035868T2 (en) * 2006-11-15 2018-05-28 Ym Biosciences Australia Pty Inhibitors of kinase activity
JP2010510202A (ja) 2006-11-17 2010-04-02 ファイザー株式会社 置換ビシクロカルボキシアミド化合物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2010533147A (ja) * 2007-07-13 2010-10-21 アデックス ファルマ エス.エイ. 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
BRPI0816095A2 (pt) * 2007-08-30 2015-03-03 Takeda Pharmaceutical Composto ou um sal do mesmo, pró-droga, agente farmacêutico, métodos para antagonizar um receptor de androgênio e para prevenir / tratar cãncer, e, uso do composto ou uma pró-droga do mesmo.
KR20100090777A (ko) 2007-10-19 2010-08-17 아스트라제네카 아베 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체
WO2009054790A1 (en) * 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2331095B1 (de) 2008-08-04 2014-10-15 CHDI Foundation, Inc. Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür
WO2010106106A1 (en) * 2009-03-19 2010-09-23 Neurosearch A/S 2, 5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators
WO2011073298A1 (en) * 2009-12-18 2011-06-23 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor modulators
US20120309792A1 (en) 2009-12-18 2012-12-06 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor modulators
CN103221397B (zh) * 2010-09-02 2016-04-13 孟山都技术公司 用于防治线虫害虫的新组合物及方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9173396B2 (en) 2010-10-22 2015-11-03 Bayer Intellectual Property Gmbh Heterocyclic compounds as pesticides
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PT2750677T (pt) 2011-08-30 2017-07-03 Chdi Foundation Inc Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos
KR101357395B1 (ko) * 2012-08-06 2014-02-05 영남대학교 산학협력단 신규한 테트라졸로 하이드라존 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (de) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Zusammensetzungen zur behandlung von magen-darm-störungen
WO2014152115A1 (en) 2013-03-15 2014-09-25 Monsanto Technology Llc N-,c-disubstituted azoles for controlling nematode pests
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
WO2016011316A1 (en) 2014-07-17 2016-01-21 Chdi Foundation, Inc. Methods and compositions for treating hiv-related disorders
MX2020006587A (es) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
CN108484452B (zh) * 2018-03-22 2020-10-27 东北师范大学 一种氟烷基磺酰腙的制备方法
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902909A1 (en) * 1989-08-11 1991-02-27 Ici Plc Nitrogen compounds
IE903911A1 (en) * 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体

Also Published As

Publication number Publication date
CA2462289A1 (en) 2003-04-10
EP1434773B1 (de) 2008-05-21
US7253190B2 (en) 2007-08-07
EP1434773A4 (de) 2005-01-12
US20040186295A1 (en) 2004-09-23
JP4303109B2 (ja) 2009-07-29
JP2005508344A (ja) 2005-03-31
AU2002341921B2 (en) 2007-05-31
AU2002341921B8 (en) 2003-04-14
CA2462289C (en) 2010-02-23
EP1434773A2 (de) 2004-07-07
WO2003029210A3 (en) 2003-11-20
DE60226756D1 (de) 2008-07-03
WO2003029210A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
ATE396186T1 (de) Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
WO2003053922A3 (en) Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
WO2003051833A3 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
ATE374194T1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
ATE490253T1 (de) Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen
NO20064032L (no) DPP-IV inhibitorer
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE602004017213D1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
ATE486600T1 (de) Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
CY1106969T1 (el) Αναστολεις dpp-iv
ATE407938T1 (de) Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
SE0302232D0 (sv) Novel Compounds
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
WO2004024074A3 (en) Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
MXPA05011962A (es) Oxiarenos substituidos.
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE370147T1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
BRPI0416678A (pt) pirazolpirimidinas
DE60207104D1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties